A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia
AffiliationLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester
MetadataShow full item record
AbstractThe drug efflux pump ABCB1 is a key driver of chemoresistance, and high expression predicts treatment failure in acute myeloid leukemia (AML). In this study, we identified and functionally validated the network of enhancers that controls expression of ABCB1. We show that exposure of leukemia cells to daunorubicin activated an integrated stress response-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound, stress-responsive enhancer. Protracted stress primed enhancers for rapid increases in activity following re-exposure of cells to daunorubicin, providing an epigenetic memory of prior drug treatment. In primary human AML, exposure of fresh blast cells to daunorubicin activated the stress-responsive enhancer and led to dose-dependent induction of ABCB1. Dynamic induction of ABCB1 by diverse stressors, including chemotherapy, facilitated escape of leukemia cells from targeted third-generation ABCB1 inhibition, providing an explanation for the failure of ABCB1 inhibitors in clinical trials. Stress-induced upregulation of ABCB1 was mitigated by combined use of the pharmacologic inhibitors U0126 and ISRIB, which inhibit stress signaling and have potential for use as adjuvants to enhance the activity of ABCB1 inhibitors. Keywords: Hematology, Oncology, Cell stress, Leukemias
CitationWilliams MS, Amaral FM, Simeoni F, Somervaille TC. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. J Clin Invest. 2020;130(3):1217-32.
JournalJournal of Clinical Investigation
- Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia.
- Authors: Williams MS, Somervaille TCP
- Issue date: 2020
- ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
- Authors: van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, Sonneveld P
- Issue date: 2006 Nov
- Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
- Authors: Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton S, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M
- Issue date: 2019 Sep 6
- Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
- Authors: Lu C, Hassan HT
- Issue date: 2006 Mar
- Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
- Authors: Qiu L, Zhou G, Cao S
- Issue date: 2020 Feb 15